Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 66

1.

Clonal Evolution of MEK/MAPK Pathway Activating Mutations in a Metastatic Colorectal Cancer Case.

Lehtomaki KI, Lahtinen LI, Rintanen N, Kuopio T, Kholova I, Makela R, Rantala JK, Kellokumpu-Lehtinen PL, Kononen J.

Anticancer Res. 2019 Nov;39(11):5867-5877. doi: 10.21873/anticanres.13791.

PMID:
31704811
2.

[Molecular pathologic diagnosis of lung cancer requires basic knowledge also from clinicians].

Lappi-Blanco E, Salmenkivi K, Kytölä S, Kononen J.

Duodecim. 2016;132(6):593-9. Review. Finnish.

PMID:
27132299
3.

[Circulating cell-free DNA as biomarker for cancer *header*].

Isomursu A, Kononen J, Kuopio T.

Duodecim. 2015;131(5):424-32. Review. Finnish.

PMID:
26237904
4.

Introducing tissue microarrays to molecular pathology.

Kallioniemi OP, Kononen J, Sauter G.

Clin Chem. 2012 Dec;58(12):1717-8. doi: 10.1373/clinchem.2012.188748. Epub 2012 Oct 11. No abstract available.

5.

The correlation between cellular size and protein expression levels--normalization for global protein profiling.

Lundberg E, Gry M, Oksvold P, Kononen J, Andersson-Svahn H, Pontén F, Uhlén M, Asplund A.

J Proteomics. 2008 Oct 7;71(4):448-60. doi: 10.1016/j.jprot.2008.06.014. Epub 2008 Jul 5.

PMID:
18656560
6.

A high-throughput strategy for protein profiling in cell microarrays using automated image analysis.

Strömberg S, Björklund MG, Asplund C, Sköllermo A, Persson A, Wester K, Kampf C, Nilsson P, Andersson AC, Uhlen M, Kononen J, Ponten F, Asplund A.

Proteomics. 2007 Jun;7(13):2142-50.

PMID:
17549799
7.

Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers.

Went P, Vasei M, Bubendorf L, Terracciano L, Tornillo L, Riede U, Kononen J, Simon R, Sauter G, Baeuerle PA.

Br J Cancer. 2006 Jan 16;94(1):128-35.

8.

Prevalence of KIT expression in human tumors.

Went PT, Dirnhofer S, Bundi M, Mirlacher M, Schraml P, Mangialaio S, Dimitrijevic S, Kononen J, Lugli A, Simon R, Sauter G.

J Clin Oncol. 2004 Nov 15;22(22):4514-22.

PMID:
15542802
9.

[Analysis of gene expression profiles among 3 epithelial ovarian tumor subtypes using cDNA and tissue microarrays].

Zheng M, Simon R, Kononen J, Sauter G, Mihatsch MJ, Moch H.

Ai Zheng. 2004 Jul;23(7):771-6. Chinese.

PMID:
15248910
10.

Signal transducer and activator of transcription-5 activation and breast cancer prognosis.

Nevalainen MT, Xie J, Torhorst J, Bubendorf L, Haas P, Kononen J, Sauter G, Rui H.

J Clin Oncol. 2004 Jun 1;22(11):2053-60.

PMID:
15169792
11.

Impaired expression of the cell cycle regulator BTG2 is common in clear cell renal cell carcinoma.

Struckmann K, Schraml P, Simon R, Elmenhorst K, Mirlacher M, Kononen J, Moch H.

Cancer Res. 2004 Mar 1;64(5):1632-8.

12.

Cyclin E overexpression and amplification in human tumours.

Schraml P, Bucher C, Bissig H, Nocito A, Haas P, Wilber K, Seelig S, Kononen J, Mihatsch MJ, Dirnhofer S, Sauter G.

J Pathol. 2003 Jul;200(3):375-82.

PMID:
12845634
13.

POU5F1 (OCT3/4) identifies cells with pluripotent potential in human germ cell tumors.

Looijenga LH, Stoop H, de Leeuw HP, de Gouveia Brazao CA, Gillis AJ, van Roozendaal KE, van Zoelen EJ, Weber RF, Wolffenbuttel KP, van Dekken H, Honecker F, Bokemeyer C, Perlman EJ, Schneider DT, Kononen J, Sauter G, Oosterhuis JW.

Cancer Res. 2003 May 1;63(9):2244-50.

14.

Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome.

van de Rijn M, Perou CM, Tibshirani R, Haas P, Kallioniemi O, Kononen J, Torhorst J, Sauter G, Zuber M, Köchli OR, Mross F, Dieterich H, Seitz R, Ross D, Botstein D, Brown P.

Am J Pathol. 2002 Dec;161(6):1991-6. Erratum in: Am J Pathol. 2003 Jul;163(1):377.

15.

High-throughput copy number analysis of 17q23 in 3520 tissue specimens by fluorescence in situ hybridization to tissue microarrays.

Andersen CL, Monni O, Wagner U, Kononen J, Bärlund M, Bucher C, Haas P, Nocito A, Bissig H, Sauter G, Kallioniemi A.

Am J Pathol. 2002 Jul;161(1):73-9.

16.

A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer.

Vahteristo P, Bartkova J, Eerola H, Syrjäkoski K, Ojala S, Kilpivaara O, Tamminen A, Kononen J, Aittomäki K, Heikkilä P, Holli K, Blomqvist C, Bartek J, Kallioniemi OP, Nevanlinna H.

Am J Hum Genet. 2002 Aug;71(2):432-8. Epub 2002 Jul 28.

17.

Clinical validation of candidate genes associated with prostate cancer progression in the CWR22 model system using tissue microarrays.

Mousses S, Bubendorf L, Wagner U, Hostetter G, Kononen J, Cornelison R, Goldberger N, Elkahloun AG, Willi N, Koivisto P, Ferhle W, Raffeld M, Sauter G, Kallioniemi OP.

Cancer Res. 2002 Mar 1;62(5):1256-60.

18.

Morphological spot counting from stacked images for automated analysis of gene copy numbers by fluorescence in situ hybridization.

Grigoryan AM, Dougherty ER, Kononen J, Bubendorf L, Hostetter G, Kallioniemi O.

J Biomed Opt. 2002 Jan;7(1):109-22.

19.

Tissue microarrays for rapid linking of molecular changes to clinical endpoints.

Torhorst J, Bucher C, Kononen J, Haas P, Zuber M, Köchli OR, Mross F, Dieterich H, Moch H, Mihatsch M, Kallioniemi OP, Sauter G.

Am J Pathol. 2001 Dec;159(6):2249-56.

20.

Amplification and overexpression of PRUNE in human sarcomas and breast carcinomas-a possible mechanism for altering the nm23-H1 activity.

Forus A, D'Angelo A, Henriksen J, Merla G, Maelandsmo GM, Flørenes VA, Olivieri S, Bjerkehagen B, Meza-Zepeda LA, del Vecchio Blanco F, Müller C, Sanvito F, Kononen J, Nesland JM, Fodstad Ø, Reymond A, Kallioniemi OP, Arrigoni G, Ballabio A, Myklebost O, Zollo M.

Oncogene. 2001 Oct 18;20(47):6881-90.

21.

Tissue microarrays (TMAs) for high-throughput molecular pathology research.

Nocito A, Kononen J, Kallioniemi OP, Sauter G.

Int J Cancer. 2001 Oct 1;94(1):1-5.

22.

CGH, cDNA and tissue microarray analyses implicate FGFR2 amplification in a small subset of breast tumors.

Heiskanen M, Kononen J, Bärlund M, Torhorst J, Sauter G, Kallioniemi A, Kallioniemi O.

Anal Cell Pathol. 2001;22(4):229-34.

23.

Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer.

Simon R, Nocito A, Hübscher T, Bucher C, Torhorst J, Schraml P, Bubendorf L, Mihatsch MM, Moch H, Wilber K, Schötzau A, Kononen J, Sauter G.

J Natl Cancer Inst. 2001 Aug 1;93(15):1141-6.

PMID:
11481385
24.

Microarrays of bladder cancer tissue are highly representative of proliferation index and histological grade.

Nocito A, Bubendorf L, Tinner EM, Süess K, Wagner U, Forster T, Kononen J, Fijan A, Bruderer J, Schmid U, Ackermann D, Maurer R, Alund G, Knönagel H, Rist M, Anabitarte M, Hering F, Hardmeier T, Schoenenberger AJ, Flury R, Jäger P, Fehr JL, Schraml P, Moch H, Mihatsch MJ, Gasser T, Sauter G.

J Pathol. 2001 Jul;194(3):349-57.

PMID:
11439368
25.

Comprehensive copy number and gene expression profiling of the 17q23 amplicon in human breast cancer.

Monni O, Barlund M, Mousses S, Kononen J, Sauter G, Heiskanen M, Paavola P, Avela K, Chen Y, Bittner ML, Kallioniemi A.

Proc Natl Acad Sci U S A. 2001 May 8;98(10):5711-6. Epub 2001 May 1.

26.

ANX7, a candidate tumor suppressor gene for prostate cancer.

Srivastava M, Bubendorf L, Srikantan V, Fossom L, Nolan L, Glasman M, Leighton X, Fehrle W, Pittaluga S, Raffeld M, Koivisto P, Willi N, Gasser TC, Kononen J, Sauter G, Kallioniemi OP, Srivastava S, Pollard HB.

Proc Natl Acad Sci U S A. 2001 Apr 10;98(8):4575-80. Epub 2001 Apr 3.

27.

Tissue microarray technology for high-throughput molecular profiling of cancer.

Kallioniemi OP, Wagner U, Kononen J, Sauter G.

Hum Mol Genet. 2001 Apr;10(7):657-62. Review.

PMID:
11257096
28.

Gene-expression profiles in hereditary breast cancer.

Hedenfalk I, Duggan D, Chen Y, Radmacher M, Bittner M, Simon R, Meltzer P, Gusterson B, Esteller M, Kallioniemi OP, Wilfond B, Borg A, Trent J, Raffeld M, Yakhini Z, Ben-Dor A, Dougherty E, Kononen J, Bubendorf L, Fehrle W, Pittaluga S, Gruvberger S, Loman N, Johannsson O, Olsson H, Sauter G.

N Engl J Med. 2001 Feb 22;344(8):539-48.

29.

CDKNA2A mutation analysis, protein expression, and deletion mapping of chromosome 9p in conventional clear-cell renal carcinomas: evidence for a second tumor suppressor gene proximal to CDKN2A.

Schraml P, Struckmann K, Bednar R, Fu W, Gasser T, Wilber K, Kononen J, Sauter G, Mihatsch MJ, Moch H.

Am J Pathol. 2001 Feb;158(2):593-601.

30.

Novel findings in gene expression detected in human osteosarcoma by cDNA microarray.

Wolf M, El-Rifai W, Tarkkanen M, Kononen J, Serra M, Eriksen EF, Elomaa I, Kallioniemi A, Kallioniemi OP, Knuutila S.

Cancer Genet Cytogenet. 2000 Dec;123(2):128-32.

PMID:
11156738
31.

Identification of differentially expressed genes in human gliomas by DNA microarray and tissue chip techniques.

Sallinen SL, Sallinen PK, Haapasalo HK, Helin HJ, Helén PT, Schraml P, Kallioniemi OP, Kononen J.

Cancer Res. 2000 Dec 1;60(23):6617-22.

32.

Loss of NKX3.1 expression in human prostate cancers correlates with tumor progression.

Bowen C, Bubendorf L, Voeller HJ, Slack R, Willi N, Sauter G, Gasser TC, Koivisto P, Lack EE, Kononen J, Kallioniemi OP, Gelmann EP.

Cancer Res. 2000 Nov 1;60(21):6111-5.

33.

Chromosome imbalances in familial gliomas detected by comparative genomic hybridization.

Paunu N, Sallinen SL, Karhu R, Miettinen H, Sallinen P, Kononen J, Laippala P, Simola KO, Helén P, Haapasalo H.

Genes Chromosomes Cancer. 2000 Dec;29(4):339-46. Review.

PMID:
11066078
34.

Multiple genes at 17q23 undergo amplification and overexpression in breast cancer.

Bärlund M, Monni O, Kononen J, Cornelison R, Torhorst J, Sauter G, Kallioniemi OLLI-P, Kallioniemi A.

Cancer Res. 2000 Oct 1;60(19):5340-4.

35.

High-throughput tissue microarray analysis of cyclin E gene amplification and overexpression in urinary bladder cancer.

Richter J, Wagner U, Kononen J, Fijan A, Bruderer J, Schmid U, Ackermann D, Maurer R, Alund G, Knönagel H, Rist M, Wilber K, Anabitarte M, Hering F, Hardmeier T, Schönenberger A, Flury R, Jäger P, Fehr JL, Schraml P, Moch H, Mihatsch MJ, Gasser T, Kallioniemi OP, Sauter G.

Am J Pathol. 2000 Sep;157(3):787-94.

36.

Detecting activation of ribosomal protein S6 kinase by complementary DNA and tissue microarray analysis.

Bärlund M, Forozan F, Kononen J, Bubendorf L, Chen Y, Bittner ML, Torhorst J, Haas P, Bucher C, Sauter G, Kallioniemi OP, Kallioniemi A.

J Natl Cancer Inst. 2000 Aug 2;92(15):1252-9.

PMID:
10922410
37.

[Identification of prognostic parameters for renal cell carcinoma by cDNA arrays and cell chips].

Moch H, Schraml P, Bubendorf L, Mirlacher M, Kononen J, Gasser T, Mihatsch MJ, Kallioniemi OP, Sauter G.

Verh Dtsch Ges Pathol. 1999;83:225-32. German.

PMID:
10714215
38.

A nuclear factor, ASC-2, as a cancer-amplified transcriptional coactivator essential for ligand-dependent transactivation by nuclear receptors in vivo.

Lee SK, Anzick SL, Choi JE, Bubendorf L, Guan XY, Jung YK, Kallioniemi OP, Kononen J, Trent JM, Azorsa D, Jhun BH, Cheong JH, Lee YC, Meltzer PS, Lee JW.

J Biol Chem. 1999 Nov 26;274(48):34283-93.

39.

Hormone therapy failure in human prostate cancer: analysis by complementary DNA and tissue microarrays.

Bubendorf L, Kolmer M, Kononen J, Koivisto P, Mousses S, Chen Y, Mahlamäki E, Schraml P, Moch H, Willi N, Elkahloun AG, Pretlow TG, Gasser TC, Mihatsch MJ, Sauter G, Kallioniemi OP.

J Natl Cancer Inst. 1999 Oct 20;91(20):1758-64.

PMID:
10528027
40.

Tissue microarrays for gene amplification surveys in many different tumor types.

Schraml P, Kononen J, Bubendorf L, Moch H, Bissig H, Nocito A, Mihatsch MJ, Kallioniemi OP, Sauter G.

Clin Cancer Res. 1999 Aug;5(8):1966-75.

41.

Cyclin D1 expression in astrocytomas is associated with cell proliferation activity and patient prognosis.

Sallinen SL, Sallinen PK, Kononen JT, Syrjäkoski KM, Nupponen NN, Rantala IS, Helén PT, Helin HJ, Haapasalo HK.

J Pathol. 1999 Jul;188(3):289-93.

PMID:
10419598
42.

Reduced Fhit expression in sporadic and BRCA2-linked breast carcinomas.

Ingvarsson S, Agnarsson BA, Sigbjornsdottir BI, Kononen J, Kallioniemi OP, Barkardottir RB, Kovatich AJ, Schwarting R, Hauck WW, Huebner K, McCue PA.

Cancer Res. 1999 Jun 1;59(11):2682-9.

43.

CDKN2/p16 predicts survival in oligodendrogliomas: comparison with astrocytomas.

Miettinen H, Kononen J, Sallinen P, Alho H, Helen P, Helin H, Kalimo H, Paljärvi L, Isola J, Haapasalo H.

J Neurooncol. 1999 Feb;41(3):205-11.

PMID:
10359140
44.

High-throughput tissue microarray analysis to evaluate genes uncovered by cDNA microarray screening in renal cell carcinoma.

Moch H, Schraml P, Bubendorf L, Mirlacher M, Kononen J, Gasser T, Mihatsch MJ, Kallioniemi OP, Sauter G.

Am J Pathol. 1999 Apr;154(4):981-6.

45.

Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays.

Bubendorf L, Kononen J, Koivisto P, Schraml P, Moch H, Gasser TC, Willi N, Mihatsch MJ, Sauter G, Kallioniemi OP.

Cancer Res. 1999 Feb 15;59(4):803-6. Erratum in: Cancer Res 1999 Mar 15;59(6):1388.

46.

Tissue microarrays for high-throughput molecular profiling of tumor specimens.

Kononen J, Bubendorf L, Kallioniemi A, Bärlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP.

Nat Med. 1998 Jul;4(7):844-7.

PMID:
9662379
47.

Accumulation of genetic changes is associated with poor prognosis in grade II astrocytomas.

Sallinen SL, Sallinen P, Haapasalo H, Kononen J, Karhu R, Helén P, Isola J.

Am J Pathol. 1997 Dec;151(6):1799-807.

48.

Genome screening by comparative genomic hybridization.

Forozan F, Karhu R, Kononen J, Kallioniemi A, Kallioniemi OP.

Trends Genet. 1997 Oct;13(10):405-9. Review.

PMID:
9351342
49.

AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer.

Anzick SL, Kononen J, Walker RL, Azorsa DO, Tanner MM, Guan XY, Sauter G, Kallioniemi OP, Trent JM, Meltzer PS.

Science. 1997 Aug 15;277(5328):965-8.

50.

Increased expression of telomerase RNA component is associated with increased cell proliferation in human astrocytomas.

Sallinen P, Miettinen H, Sallinen SL, Haapasalo H, Helin H, Kononen J.

Am J Pathol. 1997 Apr;150(4):1159-64.

Supplemental Content

Loading ...
Support Center